| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/20/2010 | US7759058 Containing active ingredient and bactericide effective against at least 2 different kinds selected from escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and enterococcus hirae |
| 07/20/2010 | US7759054 Method for detection of nitric oxide (NO) |
| 07/20/2010 | US7758902 Administering rosehips, resveratrol, astaxanthin, blackberry, blueberry, elderberry, and/or Aframomum melegueta extractto inhibit interleukin synthesis; antiinflammatory agents; cardiovascular disorders, pain, stiffness |
| 07/20/2010 | US7758899 Pharmaceutical compositions and their use in the treatment of neoplastic disease |
| 07/20/2010 | US7758898 Copper lowering treatment of inflammatory and fibrotic diseases |
| 07/20/2010 | US7758893 Enteral compositions for the prevention and/or treatment of sepsis |
| 07/20/2010 | US7758890 Treatment using dantrolene |
| 07/20/2010 | US7758889 Fullerenes in targeted therapies |
| 07/20/2010 | US7758888 Microcapsular core encapsulated within said shell and includes at least one active ingredient whereas said shell is a microcapsular shell and includes at least one inorganic polymer obtained by a sol-gel process. |
| 07/20/2010 | US7758887 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 07/20/2010 | US7758884 saponified plant extracts; incubtion; bioavailability |
| 07/20/2010 | US7758883 first layer has polyvinyl alcohol, polyvinyl acetate, and polyvinyl pyrrolidone; aqueous layer over the first layer;and a layer of a phospholipid (e.g., lecithin) over the aqueous layer; for treating dry eye syndrome |
| 07/20/2010 | US7758880 Blend of a biologically compatible structural component such as an acrylic ester (co)polymer, and a copolymer having a biobeneficial or bioactive moiety, such as a block copolymer of polyethylene glycol and a polyacrylate; coating medical devices such as stents |
| 07/20/2010 | US7758877 Storage stable liquid suspension for oral administration comprising an antihistamine selected from loratadine, descarboethoxyloratadine, azatadine and/or salts; and surfactant; oxidation resistance; water, glycerin, sorbitol, propylene glycol, and thickener |
| 07/20/2010 | US7758876 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
| 07/20/2010 | US7758864 Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin |
| 07/20/2010 | US7758863 Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 07/20/2010 | US7758858 Nucleotide sequences coding tumor necrosis factor binding proteins for prevention and treatment of bone disorders |
| 07/20/2010 | US7758693 delivering a bone substitue, water combinable combination of a calcium phosphate and a strontium phosphate and a salt of H3PO4; cement system for filling bone defects in a form-fit manner where the cement preparations are hardenable not only at room temperature, but also at body temperature; osteoporosis |
| 07/20/2010 | US7758619 Spinous process implant with tethers |
| 07/20/2010 | CA2607848C 3-substituted (3-phenyl)-propionic acid derivatives for the treatment of metabolic disorders |
| 07/20/2010 | CA2595569C Substituted triazole derivatives as oxytocin antagonists |
| 07/20/2010 | CA2547234C The use of quaternary pyridinium salts as vasoprotective agents |
| 07/20/2010 | CA2539297C Substituted triazole derivatives as oxytocin antagonists |
| 07/20/2010 | CA2532049C Isethionate salt of a selective cdk4 inhibitor |
| 07/20/2010 | CA2529983C Preoperative treatment of post operative pain |
| 07/20/2010 | CA2502416C N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents |
| 07/20/2010 | CA2490170C Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury |
| 07/20/2010 | CA2489855C Sustained-release tramadol formulations with 24-hour clinical efficacy |
| 07/20/2010 | CA2486399C Calcium receptor modulating agents |
| 07/20/2010 | CA2472685C Method of treatment of gastrointestinal disease and polymeric composition for use therein |
| 07/20/2010 | CA2455680C Ophthalmic depot formulations for periocular or subconjunctival administration |
| 07/20/2010 | CA2454732C Drugs for ameliorating postcibal hyperglycemia |
| 07/20/2010 | CA2448798C Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 07/20/2010 | CA2447865C Novel sulfonic acid derivatives |
| 07/20/2010 | CA2446942C Use of il-18 inhibitors for the treatment or prevention of sepsis |
| 07/20/2010 | CA2444533C Pharmaceutical vehicle |
| 07/20/2010 | CA2442415C Medical aerosol formulations |
| 07/20/2010 | CA2431982C Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
| 07/20/2010 | CA2423857C Malonamide and malonamic ester derivatives with antithrombotic activity |
| 07/20/2010 | CA2411831C Pharmaceutical compositions comprising cannabidiol derivatives |
| 07/20/2010 | CA2406077C Formulation for the prevention of cardiovascular disease |
| 07/20/2010 | CA2399001C Integrin expression inhibitor |
| 07/20/2010 | CA2378106C Bioavailable chelates of creatine and essential metals |
| 07/20/2010 | CA2377290C Utilization of a highly fluorinated oligomeric alkane in ophthalmology |
| 07/20/2010 | CA2350651C Novel erythromycin derivatives, preparation method and use as medicines |
| 07/20/2010 | CA2340931C 3'-deoxypentopyranosylnucleic acid, its preparation and use |
| 07/20/2010 | CA2322487C Novel prodrugs for phosphorus-containing compounds |
| 07/20/2010 | CA2290136C New erythromycin derivatives, the process for preparing them and their use as a drug product |
| 07/20/2010 | CA2288983C Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 07/20/2010 | CA2282906C Stable complexes of poorly soluble compounds |
| 07/20/2010 | CA2271249C Macromolecular neuraminidase-binding compounds |
| 07/20/2010 | CA2266908C O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates |
| 07/20/2010 | CA2246733C Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| 07/20/2010 | CA2197563C Capsular polysaccharide immunomodulator |
| 07/20/2010 | CA2197235C Adenovirus comprising a gene coding for glutathion peroxidase |
| 07/17/2010 | WO2010067131A1 P38 map kinase inhibitors |
| 07/15/2010 | WO2010081172A1 Methods for treating vascular leak syndrome |
| 07/15/2010 | WO2010081149A1 Anti-viral compounds, compositions, and methods of use |
| 07/15/2010 | WO2010081145A1 Anti-viral compounds, compositions, and methods of use |
| 07/15/2010 | WO2010081115A1 Pro-neurogenic compounds |
| 07/15/2010 | WO2010081104A1 Use of polymeri zable quaternary ammonium compounds to inhibit endogenous mmps in tooth dentin |
| 07/15/2010 | WO2010081082A2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| 07/15/2010 | WO2010081079A2 Composition and method for treatment of diabetes |
| 07/15/2010 | WO2010081070A2 Novel forms of eperisone |
| 07/15/2010 | WO2010081049A1 Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates |
| 07/15/2010 | WO2010081032A2 Steroidal compositions |
| 07/15/2010 | WO2010081022A1 Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia |
| 07/15/2010 | WO2010080996A1 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| 07/15/2010 | WO2010080977A2 Oral sustained release antidepressant formulation |
| 07/15/2010 | WO2010080971A1 Crystalline polymorphic forms of an antidiabetic compound |
| 07/15/2010 | WO2010080970A2 Oral enteric antidepressant formulation |
| 07/15/2010 | WO2010080964A1 Method for treating hyperglycemia with glp-1 |
| 07/15/2010 | WO2010080878A1 Combination of a cyclosporine derivative and nucleosides for treating hcv |
| 07/15/2010 | WO2010080873A1 Oxazoles as modulators of chemokine receptors |
| 07/15/2010 | WO2010080831A1 Method of treating neuropathic pain |
| 07/15/2010 | WO2010080817A2 Carbohydrate-cyclopamine conjugates as anticancer agents |
| 07/15/2010 | WO2010080811A1 A composition and method of treating facial skin defect |
| 07/15/2010 | WO2010080769A2 Chemotherapeutic methods and compositions |
| 07/15/2010 | WO2010080756A2 Harmine derivatives for reducing body weight |
| 07/15/2010 | WO2010080730A2 Methods and materials for delivering bile acids |
| 07/15/2010 | WO2010080724A1 Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| 07/15/2010 | WO2010080712A2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| 07/15/2010 | WO2010080652A1 Chlorhexidine acetate antiseptic cleaning agent |
| 07/15/2010 | WO2010080603A2 Method of treatment of aggression |
| 07/15/2010 | WO2010080581A2 Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use |
| 07/15/2010 | WO2010080577A2 Oxepine modulators of h1 receptors and/or inhibitors of mast cell degranulation |
| 07/15/2010 | WO2010080563A2 Method for treating macular degeneration |
| 07/15/2010 | WO2010080558A1 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| 07/15/2010 | WO2010080554A1 Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| 07/15/2010 | WO2010080540A1 Method for treating inflammatory conditions |
| 07/15/2010 | WO2010080537A1 Gpr120 receptor agonists and uses thereof |
| 07/15/2010 | WO2010080509A1 Compositions and methods for diminishing viral infection and inflammation associated with viral infection |
| 07/15/2010 | WO2010080481A1 Carbazole carboxamide compounds useful as kinase inhibitors |
| 07/15/2010 | WO2010080478A1 Compounds and methods of use |
| 07/15/2010 | WO2010080474A1 Carbazole and carboline kinase inhibitors |
| 07/15/2010 | WO2010080455A1 New salts |
| 07/15/2010 | WO2010080452A2 siRNA COMPOUNDS AND METHODS OF USE THEREOF |
| 07/15/2010 | WO2010080415A2 Substituted afpo (6-aryl-4h-furo[3,2-c]pyran-4-one) derivatives as anti-cancer agents |
| 07/15/2010 | WO2010080414A2 Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents |